1[1]Finkielstein D,Schweitzer P.Role of angiotensin-converting enzyme inhibitors in the prevention of atrial fibrillation[J].Am J Cardiol,2004,93(6):734-736.
2[2]Pandozi C,Santini M.Update on atrial remodelling owing to rate:does atrial fibrillation always 'beget' atrial fibrillation?[J].Eur Heart J,2001,22(7):541-553.
3[3]Sanders P,Morton JB,Davidson NC,et al.Electrical remodeling of the atria in congestive heart failure:electrophysiological and electroanatomic mapping in humans[J].Circulation,2003,108(12):1461-1468.
4[4]Todd DM,Skanes AC,Guiraudon G,et al.Role of the posterior left atrium and pulmonary veins in human lone atrial fibrillation:electrophysiological and pathological data from patients undergoing atrial fibrillation surgery[J].Circulation,2003,108(25):3108-3114.
5[5]Kumagai K,Nakashima H,Urata H,et al.Effects of angiotensin Ⅱ type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation[J].J Am Coll Cardiol,2003,41(12):2197-2204.
6[6]Maggioni AP,Latini R,Carson PE,et al.Valsartan reduces the incidence of atrial fibrillation in patients with heart failure:results from the Valsartan Heart Failure Trial (ValHeFT)[J].Am Heart J,2005,149(5):548-557.
7[7]Unger T.The role of the renin-angiotensin system in the development of cardiovascular disease[J].Am J Cardiol,2002,89(2A):3A-9A.
8[8]Kalus J,Coleman C,White C.The impact of suppressing the renin-angiotensin system on atrial fibrillation[J].Clin Pharmacol,2006,46(1):21-28.
9[9]Touyz RM,Sventck P,Lariviere R,et al.Cytosolic cacium changes induced by angiotensin Ⅱ in neonatal rat atrial and ventricular cardiomyocytes are mediated via angiotensin Ⅱ subtype Ⅰ receptors[J].Hypertension,1996,27(5):1090-1096.
10[10]Everett TH 4th,Li H,Mangrum JM,et al.Electrical,morphological,and ultrastructural remodilling and reverse remodeling in a canine model of chronic atrial fibrillation[J].Circulation,2000,102(12):1453-1460.
2R Mizuno, S Fujumoto, H Nakano. Atrial conduction abnormalityin patients with systemic progressive sclerosis [ J]. Eur Heart J, 1997,18 : 1995 - 2001.
3Goette A, Arndt M, Rocken C, et al. Regulation of an - giotensin II receptor subtype during atrial fibrillation in humans [ J ]. Circulation, 2000,101 : 2678.
4Kumagai K, Nakashima H, Urata H ,et al. Effects of angiotensin II type l receptor antagonist on electrical and structural remodeling in atrialfibrillation[ J]. J Am Coll Cardiol,2003,41 (12) :2197.
5Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular Morbidity andmortality in hypertensive patients with a history of atrial fibrillation; thelosartan intervention for end point reduction in hypertension ( LIFE ) study [ J ]. J Am Coll Cardiol,2005,45 (5) 705 - 711.
6MiyatakeK, Yamagishi M, Tanaka N, et al. A new method for theevaluation of left ventricular wall motion by color - coded tissue Dopplerimaging:in vitro and in vivo_studies [J]. J Am Coll Cardiol, 1995,25:717.
7Martinez Lopez JI. Pauses and causes[ J]. J La State Med Soc. 1996.148 (4) : 139 - 141.
